United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 2, 2020-- Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) (“Endologix” or the “Company”) today announced the first implant of its recently approved ALTO ® endograft outside of the United States , completed by
View HTML
Toggle Summary Endologix Receives CE Mark for ALTO Abdominal Stent Graft System
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Transforming the treatment of aortic disorders, Endologix ® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced that it has received a CE Mark for the ALTO™ Abdominal Stent Graft System (ALTO).
View HTML
Toggle Summary Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System & Official Start of U.S. Commercial Release
IRVINE, Calif.--( BUSINESS WIRE )--Transforming the treatment of aortic disorders, Endologix® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced the first commercial implant and the U.S. commercial release of its recently FDA-approved ALTO® endograft for the treatment of abdominal
View HTML
Toggle Summary Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private
  Commences voluntary Chapter 11 process with access to $30.8 million in DIP financing Files consensual plan of reorganization that would reduce approximately $180 million in debt and provide an approximately $30 million in additional exit financing Confirms launch of Alto this summer, steady
View HTML
Toggle Summary Endologix Announces Departure of CFO and Appointment of Interim CFO
IRVINE, Calif. --(BUSINESS WIRE)--Jun. 18, 2020-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob , Chief Financial Officer (CFO), will be departing the Company effective July
View HTML
Toggle Summary Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System
IRVINE, Calif. --(BUSINESS WIRE)--Jun. 15, 2020-- Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root
View HTML
Toggle Summary Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System
IRVINE, Calif. --(BUSINESS WIRE)--May 11, 2020-- Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix
View HTML
Toggle Summary Endologix Reports First Quarter 2020 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--May 11, 2020-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020 . The Company’s financial results are preliminary
View HTML
Toggle Summary Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020
IRVINE, Calif. --(BUSINESS WIRE)--May 1, 2020-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after the market close on Monday, May 11, 2020 .
View HTML
Toggle Summary Endologix Appoints Tim A. Benner as Chief Commercial Officer
IRVINE, Calif. --(BUSINESS WIRE)--Apr. 14, 2020-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John Zehren as the Company’s Chief Commercial
View HTML
Toggle Summary Endologix Announces Preliminary Financial Results for First Quarter 2020
IRVINE, Calif. --(BUSINESS WIRE)--Apr. 6, 2020-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Mar. 30, 2020-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees (the “Awardees”).
View HTML
Toggle Summary Endologix Adds Jane E. Kiernan to its Board of Directors
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jane E. Kiernan to its board of directors, effective March 12, 2020 . Ms.
View HTML
Toggle Summary Endologix Receives FDA Approval for Alto Abdominal Stent Graft System
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™ Abdominal
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the “Awardee”).
View HTML